论文部分内容阅读
目的探讨2周CHOP方案治疗弥漫大B细胞淋巴瘤(DLBCL)的临床疗效。方法 17例DLBCL患者,因经济原因不能使用利妥昔单抗,给予2周的CHOP方案化疗,现对治疗结果进行回顾性分析。结果经治疗6~8个疗程后,完全缓解(CR)3例(17.65%)、部分缓解(PR)9例(52.94%),病情稳定(NC)3例(17.65%),病情进展(PD)2例(11.76%),治疗总有效率为70.59%。1年无进展生存率58.82%,1年总生存率为88.24%。2年无进展生存率41.18%,2年总生存率为64.71%。不良反应主要表现在骨髓抑制方面,其中发生Ⅰ、Ⅱ、Ⅲ度骨髓抑制患者分别有3、9、5例,在加强粒细胞集落刺激因子(G-CSF)的应用后,无Ⅳ度骨髓抑制患者。结论 2周CHOP方案治疗DLBCL,对比文献数据,疗效要优于3周CHOP方案,差于R-CHOP方案,并且在加强G-CSF的支持后,副作用没有明显增加,并未出现Ⅳ度骨髓抑制。值得在经济欠发达地区、基层医院推广应用。
Objective To investigate the clinical efficacy of 2 weeks CHOP regimen in the treatment of diffuse large B cell lymphoma (DLBCL). Methods Seventeen patients with DLBCL who were unable to use rituximab for economic reasons and were given CHOP regimen for two weeks were retrospectively analyzed. Results After 6 to 8 courses of treatment, there were 3 cases (17.65%) of complete remission (CR), 9 cases (52.94%) of partial remission (PR), 3 cases (17.65%) of stable condition (NC) ) In 2 cases (11.76%), the total effective rate was 70.59%. The 1-year progression-free survival rate was 58.82% and the 1-year overall survival rate was 88.24%. 2-year progression-free survival rate was 41.18%, 2-year overall survival rate was 64.71%. Adverse reactions mainly in bone marrow suppression, in which I, II, III degrees of myelosuppression in patients with 3,9,5 cases, respectively, in the strengthening of granulocyte colony stimulating factor (G-CSF) application, no degree of myelosuppression patient. Conclusions The 2-week CHOP regimen is superior to the 3-week CHOP regimen in the treatment of DLBCL compared with the literature data, which is worse than the R-CHOP regimen. There was no significant increase in the side effects with G-CSF support and no grade IV myelosuppression . Worthy of promotion and application in the underdeveloped areas and primary hospitals.